Author(s): Ribera JM, Oriol A
Abstract Share this page
Abstract Today, long-term survival is achieved in more than 80\% of children 1 to 10 years old with acute lymphoblastic leukemia (ALL). However, cure rates for adults and adolescents and young adults (AYA) with ALL remain relatively low, at only 40\% to 50\%. Age is a continuous prognostic variable in ALL, with no single age at which prognosis deteriorates markedly. Within childhood ALL populations, older children have shown inferior outcomes, whereas younger adults have shown superior outcomes among adult ALL patients. The type of treatment (pediatric-based versus adult-based) for AYA has recently been a matter of debate. In this article the biology and treatment of ALL in AYA is reviewed.
This article was published in Hematol Oncol Clin North Am
and referenced in Journal of Antivirals & Antiretrovirals